- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01871376
Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation (EPIC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, randomized, one-year, multiple-dose study of 2mg aflibercept in patients with PCV.
The study consists of the baseline visit on day 0 and a mandatory clinic visit every 30 days to assess efficacy and safety. All patients will receive three monthly injections of 2mg intravitreal aflibercept injection followed by treatment every 60 days through 720 days (24 months). Patients can be treated every 30 days if needed.
The fellow eye may be treated with intravitreal aflibercept injection per the investigator's discretion at any point during the study if evidence of disease activity are met: exudation or hemorrhage secondary to polypoidal choroidal vasculopathy or exudative AMD. The fellow eye will not be considered the study eye. If treatment with aflibercept is to be given in the fellow eye, the injections are to be administered according to the Food and Drug Administration (FDA) approved label for EYLEA®.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Hawaii
-
Aiea, Hawaii, United States, 96701
- Retina Consultants of Hawaii
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 25 years of age.
- In the opinion of the principal investigator, the study eye has PCV with active exudation and/or bleeding that may benefit from treatment with study medication.
- Diagnosis of PCV via ICG Angiography with evidence of active leakage, active bleeding or recent decreased in vision.
- Baseline visual acuity better than or equal to 20/200 using ETDRS
- Willing and able to comply with clinic visits and study-related procedures
- Provide signed informed consent
Exclusion Criteria:
- Any history of previous vitrectomy
- Previous cataract surgery within the preceding 2 months of Day 0
- Active infections conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
- Presence of any condition that would jeopardize the patient's participation in this study
- Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval at the time of study entry
- For the Treatment-Naïve cohort: no prior anti-VEGF (Macugen, Avastin, Lucentis, Eylea) in the study eye
- For the Previous-Treated cohort: no prior anti-VEGF (Macugen, Avastin, Lucentis) in the study eye within 30 days or enrollment in this study
- For the Previous-Treated cohort: no prior Eylea in the study eye
- Known allergy to any component of the study drug
- Blood pressure >180/119 (systolic above 180 or diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, the patient can be eligible.
- Major surgery within 28 days prior to randomization or major surgery planned within the next 12 months. Major surgery is defined as a surgical procedure that is more extensive than needle biopsy/aspiration placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter
- Myocardial infarction, other cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 6 months prior to randomization
- Systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomization
- Pregnant or breast-feeding women
- Simultaneous participation in another medical investigational trial
- Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Previously Treated
Patients that have previously received treatment for polypoidal choroidal vasculopathy. Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for previously treated arm. |
Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
Other Names:
|
Active Comparator: Treatment-Naive
Patients that have not received treatment for polypoidal choroidal vasculopathy. Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for treatment-naive arm. |
Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
efficacy of intravitreal aflibercept injection of 2.0mg aflibercept
Time Frame: 2 Years
|
This study will evaluate the efficacy of intravitreal aflibercept injection of 2.0mg aflibercept administered Q8W following an initial loading dose of 3 monthly injections in patients with polypoidal choroidal vasculopathy with active exudation or bleeding as measured by: • Mean change in BCVA between Day 0 (Baseline) and Day 720 (M24) |
2 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients with Stable, Improved, Significant Improved, Decreased, Significant Decreased Vision
Time Frame: 6 Months, 12 Months, 18 Months, 24 Months
|
To evaluate the proportion of patients at Day 180 (M6), Day 360 (M12), Day 540 (M18) and Day 720 (M24) with "Stable" vision <5 letters gained or lost, "Improved" vision >5 letters gained, "Significant Improved" vision ≥15 letters gained, "Decreased" vision >5 letters lost, "Significant Decreased" vision ≥15 letters lost
|
6 Months, 12 Months, 18 Months, 24 Months
|
Proportion of Patients with decrease in Subretinal Hemorrhage and/or Exudates
Time Frame: Month 6, Month 12, Month 18, Month 24
|
To evaluate the proportion of patients at Day 180 (M6), Day 360 (M12), Day 540 (M18), Day 720 (M24) in decreasing subretinal hemorrhage and/or subretinal exudates via fundus photos and fundus exams
|
Month 6, Month 12, Month 18, Month 24
|
Proportion of patients with decreased / complete resolution of Polypoidal Polyp.
Time Frame: Month 3, Month 6, Month 12, Month 18, Month 24
|
To evaluate the proportion of subjects with a decrease and/or complete resolution of polypoidal polyps from PCV at Day 90 (M3), Day 180 (M6), Day 360 (M12), Day 540 (M18) and Day 720 (M24) as assessed by fluorescein and indocyanine green angiography
|
Month 3, Month 6, Month 12, Month 18, Month 24
|
Proportion of subject with a decrease or complete resolution of branching vascular network from PCV
Time Frame: Month 3, Month 6, Month 12, Month 18, Month 24
|
To identify the proportion of subjects with a decrease and/or complete resolution of branching vascular network (BVN) from PCV at Day 90 (M3), Day 180 (M6), Day 360 (M12), Day 540 (M18) and 720 (M24) months as assessed by fluorescein and indocyanine green angiography
|
Month 3, Month 6, Month 12, Month 18, Month 24
|
Determine mean change in Central Foveal Thickness and/or peripapillary edema as measured by SD-OCT
Time Frame: Baseline, Month 6, Month 12, Month 18, Month 24
|
To determine mean change in central foveal thickness (CFT) and/or peripapillary edema as measured by spectral domain optical coherence tomography (SD-OCT) in central and/or paracentral fields from Day 0 (Baseline), Day 180 (M6), Day 360 (M12), Day 540 (M18) and 720 (M24)
|
Baseline, Month 6, Month 12, Month 18, Month 24
|
Mean Change in Choroidal Thickness
Time Frame: Baseline, Month 6, Month 12, Month 18, Month 24
|
To determine mean change in choroidal thickness (at fovea) as imaged via EDI-OCT between Day 0 (Baseline), Day 180 (M6), Day 360 (M12), Day 540 (M18), and Day 720 (M24)
|
Baseline, Month 6, Month 12, Month 18, Month 24
|
Proportion of previously treated and treatment naive patients that require additional dosing outside of the protocol determined dosing schedule
Time Frame: Month 24
|
To identify proportion of patients between previously treated and treatment naïve patients that require additional dosing outside of the protocol determined dosing schedule: 3- initial monthly dosing followed by dosing every other month for 720 days (M24)
|
Month 24
|
Assess changes on Autofluorescence
Time Frame: Baseline, Month 6, Month 12, Month 18, Month 24
|
To assess changes on autofluorescence (AF) as seen on images from Day 1 (Baseline), Day 180 (M6), Day 360 (M12), Day 540 (M18) and Day 720 (M24)
|
Baseline, Month 6, Month 12, Month 18, Month 24
|
Incidence and Severity of Ocular and Non-Ocular Adverse Events
Time Frame: Baseline through Month 24
|
To determine the incidence and severity of ocular and non-ocular adverse events from Day 1(Baseline) through the end of the study (Day 720)
|
Baseline through Month 24
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gregg T. Kokame, MD, MMS, Hawaii Pacific Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPIC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polypoidal Choroidal Vasculopathy
-
Ophthotech CorporationCompletedIdiopathic Polypoidal Choroidal VasculopathyUnited States
-
Ophthotech CorporationWithdrawnIdiopathic Polypoidal Choroidal VasculopathyUnited States
-
Peking Union Medical College HospitalBayerRecruitingPolypoidal Choroidal VasculopathyChina
-
Federico II UniversityCompleted
-
Sun Yat-sen UniversityCompletedPolypoidal Choroidal VasculopathyChina
-
Nihon UniversityCompletedPolypoidal Choroidal VasculopathyJapan
-
Chiang Mai UniversityRecruitingPolypoidal Choroidal VasculopathyThailand
-
Mateon TherapeuticsCompletedPolypoidal Choroidal VasculopathyUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
Seoul St. Mary's HospitalUnknownPolypoidal Choroidal VasculopathyKorea, Republic of
-
Xiaodong SunShanghai Zhongshan Hospital; Eye & ENT Hospital of Fudan UniversityUnknownPolypoidal Choroidal VasculopathyChina
Clinical Trials on Intravitreal aflibercept injection 2.0mg
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Innovent Biologics (Suzhou) Co. Ltd.SuspendedDiabetic Macular Edema | Neovascular Age-related Macular DegenerationChina
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Germany, Hong Kong, Lithuania, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Singapore, Spain, Switzerland, Taiwan
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom
-
M. Ali Khan, MDUniversity of California, Los Angeles; Southeastern Retina Associates; Eye Associates...RecruitingProliferative Vitreoretinopathy | Retinal Detachment With Multiple Breaks, Unspecified EyeUnited States
-
Kim's Eye HospitalBayerRecruitingRetinal Angiomatous ProliferationKorea, Republic of
-
Instituto de Olhos de GoianiaUnknownChoroidal Retinal NeovascularizationBrazil
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Regeneron PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Regeneron PharmaceuticalsBayerCompleted